FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL										
	OMB Number:	3235-0287									
Ш	Estimated average b	urden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

					01 (Occilo	00() (31 1110	investment c	company A	7. O. 10-10								
Name and Address of Reporting Person* Nicaise Claude					2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [SRPT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
<u>Inicaise Ciaude</u>					_		_					X Direct	or		10% Ov	vner			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/02/2015							Office below	r (give title)		Other (s below)	specify		
215 FIRST STREET, SUITE 7					_														
(Street)					4. If	Amer	ndment,	Date	of Original Fi	Filed (Month/Day/Year)			Individual or Joint/Group Filing (Check Applicable Line)						
CAMBRIDGE MA 02142												X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(State) (Zip)												Person						
		Tab	lo I Nor	Doriv	otivo	Soc	uritio	- A c	quired, D	ionocod	of or D	noficio	Ily Owns	۸ 					
			ie i - Noi						<u> </u>	_									
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Ins	Transaction Disposed Of Code (Instr. 5)			Benefic Owned	es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
						Code V	Amoun	t (A) (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Datif any (Month/Day/Ye	Date,	Code (Inst		on of I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactic (Instr. 4)	Ownersh S Form: Ully Direct (D Or Indirect (I) (Instr.	Ownership	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Non- Qualified Stock Option (right to buy)	\$25.18	06/02/2015			A		9,746		(1)	06/02/2025	Common	9,746	\$0.0	9,746	5	D			

Explanation of Responses:

1. This option will vest at a rate of 25% annually over four years on the earlier of (i) the anniversary date of the grant and (ii) the date of the annual meeting of our stockholders in the year following the date of grant.

By: David Tyronne Howton For: Claude Nicaise, M.D.

06/04/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.